Knight Therapeutics Inc. has entered into an asset purchase agreement with Orphan Canada Inc. related to the Canadian rights for ATryn(R) and PHOTOFRIN(R) (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. As part of the agreement, Jason Flowerday and Joost van der Mark, the founders of Orphan, will join the Knight leadership team; Jason as the Vice President Commercial Operations and Joost as Vice President Corporate Development.